Teduglutide
Gattex · Revestive · ALX-0600 · [Gly2]hGLP-2
Last updated
At a glance
Overview
Teduglutide is the heavy artillery of gut-repair peptides — a DPP-4-resistant GLP-2 analog that does to the intestinal mucosa what BPC-157 wishes it could. Originally developed for short bowel syndrome, it has migrated into the bodybuilding and looksmaxxing community as a short-course tool for rebuilding villus architecture, tightening the gut barrier, and restoring absorptive capacity after the kind of abuse heavy orals, chronic NSAIDs, GLP-1 cuts, and extreme contest prep inflict on the GI tract. Documented effects include increased villus height, deeper crypts, reduced paracellular permeability, and slowed gastric transit — a coordinated mucosal remodel rather than a vague "gut healing" claim.
The clinical evidence base is unusually solid for a peptide this niche. The STEPS program demonstrated that 0.05 mg/kg/day SC produced measurable mucosal hypertrophy and improved nutrient absorption over 24 weeks, with sustained effect in long-term extensions. Community use diverges from the label in two directions: shorter courses (4–12 weeks rather than indefinite) and lower fixed doses (1–2.5 mg/day rather than per-kg dosing), driven mainly by cost and by appropriate caution around chronic proliferative signaling in healthy subjects.
"Treatment with 0.05 mg/kg/day teduglutide for 24 weeks in patients with SBS resulted in a significant reduction in parenteral support requirements, accompanied by increases in plasma citrulline, villus height, and crypt depth." — Jeppesen et al., Gut (2011)
The sections below cover teduglutide dosage and weight-based scaling, the ~2-hour half-life and its implications for once-daily SC administration, documented stacks with BPC-157 / KPV / glutamine, use-case protocols for AAS-driven gut damage and post-GLP-1 mucosal recovery, and the side-effect profile — including the colonoscopy and pancreatic-enzyme monitoring that the pro-proliferative mechanism makes non-negotiable.
How Teduglutide works
GLP-2 Receptor Agonism and DPP-4 Resistance#
Teduglutide is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 with a single Ala²→Gly² substitution. That one swap blocks cleavage by dipeptidyl peptidase-4 (DPP-4), extending the plasma half-life from roughly 7 minutes (native GLP-2) to approximately 2 hours — long enough for once-daily subcutaneous dosing to drive sustained receptor occupancy.
The target is the GLP-2 receptor (GLP-2R), a class B GPCR expressed on enteroendocrine L-cells, subepithelial myofibroblasts, and enteric neurons of the small and large intestine. The receptor is not expressed on enterocytes themselves — GLP-2R activation works through paracrine release of IGF-1, IGF-2, KGF, and ErbB ligands from myofibroblasts, which then act on crypt stem cells to drive the downstream proliferative cascade.
"Teduglutide, a recombinant GLP-2 analog with a prolonged half-life due to resistance to DPP-4 degradation, stimulates intestinal mucosal growth and enhances absorption in patients with SBS-IF." — Pironi L. et al., Nutr Clin Pract, 2024
Practical takeaway: the half-life is short but the biological effect outlasts plasma exposure by weeks. Mucosal remodeling builds over 4–8 weeks and regresses over a similar timeframe after discontinuation. This is why community protocols are short structured courses rather than every-other-day pulsing — the receptor signal needs sustained daily delivery to drive the trophic response.
Villus Height and Crypt Depth — Mucosal Hypertrophy#
The hallmark effect of GLP-2R agonism is intestinotrophy: expansion of absorptive surface area through increased villus height, deeper crypts, and proliferation of crypt stem cells with simultaneous reduction in enterocyte apoptosis. Plasma citrulline — a biomarker of total enterocyte mass — rises measurably within weeks of dosing.
"Treatment with 0.05 mg/kg/day teduglutide for 24 weeks in patients with SBS resulted in a significant reduction in parenteral support requirements, accompanied by increases in plasma citrulline, villus height, and crypt depth." — Jeppesen PB. et al., Gut, 2011
For the physique-focused user, this is the mechanism that underwrites the nutrient-absorption and bulking-tolerance use cases. More functional enterocyte mass means more surface area for amino acid, glucose, and lipid uptake — and a higher ceiling before GI tolerance limits caloric intake. It is also the mechanism that drives the proliferative-risk caveat: anything that pushes crypt mitosis bidirectionally amplifies the growth signal in pre-existing adenomatous tissue, which is why baseline colonoscopy is non-negotiable for chronic protocols.
Transit Slowing and Mesenteric Blood Flow#
GLP-2R signaling reduces gastric emptying rate and gastric acid secretion while increasing mesenteric blood flow. The combined effect is longer luminal contact time between nutrients and a better-perfused, larger-surface-area mucosa.
This is the mechanism that matters for the GLP-1 / tirzepatide stacking discussion. GLP-1 agonists slow transit through a different pathway (central and vagal); GLP-2 agonism slows it via the gut itself while simultaneously expanding the absorptive machinery. The two effects are complementary at the transit level but opposite at the trophic level — GLP-1 chronic exposure is associated with mucosal thinning signals in preclinical work, while GLP-2 drives the opposite. This is the rationale for the post-cut "gut-reset" protocol after a tirzepatide run.
Tight-Junction Integrity and Barrier Repair#
Beyond the trophic effect on villus architecture, teduglutide tightens the paracellular barrier between enterocytes. GLP-2R activation upregulates tight-junction proteins (ZO-1, occludin, claudins) and reduces translocation of luminal endotoxin (LPS) into portal circulation. The downstream effect is reduced systemic low-grade inflammation — the same "leaky gut → metabolic inflammation" axis that has made GLP-2R agonism an active research target in obesity and metabolic disease.
"GLP-2 analogs such as teduglutide have demonstrated the ability to preserve intestinal barrier integrity and reduce low-grade inflammation in preclinical studies." — Pálsson TG. et al., Peptides, 2024
Practical takeaway: this is the mechanism community users are targeting when they run short courses after heavy 17α-alkylated oral cycles, chronic NSAID exposure, or prolonged caloric restriction. All three insults degrade tight-junction integrity; teduglutide restores it from the receptor level rather than just feeding the mucosa substrate (as glutamine or butyrate do). It is also why the canonical teduglutide + BPC-157 + KPV stack works mechanistically — three distinct entry points into the same repair phenotype.
Trophic Crosstalk with the GH / IGF-1 Axis#
The downstream effector of GLP-2R signaling is largely IGF-1 released locally from subepithelial myofibroblasts. This is why GLP-2R knockout in animal models abolishes the intestinotrophic effect of GLP-2 — without local IGF-1 release, the mucosal growth signal does not propagate to crypt stem cells.
The practical implication for stackers: systemic GH, tesamorelin, CJC/ipamorelin, or exogenous IGF-1 all raise the substrate pool that GLP-2R signaling depends on, which is why anecdotal reports describe amplified mucosal response when teduglutide is layered onto an existing GH protocol. The same logic argues for restraint — additive proliferative tone across multiple growth axes is the exact signal that warrants the polyp-screening discipline outlined in the clinical label.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.5–1 mg/kg | Once daily | Documented entry-level range |
| Mid | 1–2.5 mg/kg | Once daily | Most commonly studied range |
| High | 2.5–5 mg/kg | Once daily | Once daily SC, rotating injection sites (abdomen, thigh, upper arm). Clinical label dose is 0.05 mg/kg/day; community gut-repair protocols typically run sub-label fixed doses of 1–2.5 mg/day for cost reasons. |
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
12 wks
Cycle Length & Protocol#
Teduglutide protocols in the bodybuilding and looksmaxxing context diverge sharply from the clinical SBS paradigm. Where short bowel syndrome management runs the compound indefinitely at 0.05 mg/kg/day, community use is almost universally short, finite courses — driven by cost, the proliferative-signal caveat, and the observation that mucosal remodeling builds and holds within weeks rather than requiring chronic exposure.
Dose Ladder by Goal#
| Use Case | Cycle Length | Daily Dose (SC) |
|---|---|---|
| Gut-barrier repair after heavy oral AAS / NSAID exposure | 4–8 weeks | 1–2.5 mg |
| Mucosal recovery post-contest prep / extended deficit | 4–6 weeks | 1–1.5 mg |
| Post-GLP-1 villus restoration | 4 weeks | 1 mg |
| Absorption optimization on aggressive bulk | 6–8 weeks | 1–2 mg |
| IBD-adjacent / dysbiosis (off-label, community dose) | 8–12 weeks | 1–2 mg |
| Clinical-equivalent gut repair (label dose) | 4–8 weeks | 0.05 mg/kg |
Onset & Timing#
The intestinotrophic effect is slow-build, not acute. Plasma half-life is roughly 2 hours, but the pharmacodynamic adaptation — villus height, crypt depth, tight-junction integrity — accumulates over weeks. Subjective changes (reduced bloat, improved stool form, better tolerance of high-volume meals) typically appear at the 4-week mark, with the strongest signal between weeks 6 and 8.
"Treatment with 0.05 mg/kg/day teduglutide for 24 weeks in patients with SBS resulted in a significant reduction in parenteral support requirements, accompanied by increases in plasma citrulline, villus height, and crypt depth." — Jeppesen et al., Gut (2011)
Anyone expecting BPC-157-style first-week subjective effects will be disappointed. The compound is doing structural work, not symptomatic damping.
Loading & Tapering#
No loading phase is required or supported by the literature. Once-daily dosing reaches a stable pharmacodynamic effect without front-loading, and no accumulation occurs across days given the ~2-hour half-life.
"Teduglutide, a recombinant GLP-2 analog with a prolonged half-life due to resistance to DPP-4 degradation, stimulates intestinal mucosal growth and enhances absorption in patients with SBS-IF." — Pironi et al., Nutr Clin Pract (2024)
No taper is required on cessation. There is no HPG-axis involvement, no receptor downregulation rebound, and no withdrawal phenomenon. Mucosal architecture does regress toward baseline over weeks-to-months after discontinuation — which is why some users run a second course 3–6 months later rather than tapering off a chronic course.
On-Cycle Bloodwork Cadence#
Even short community courses warrant baseline labs because of the pancreatic and hepatobiliary signal in the clinical data:
| Timepoint | Panel |
|---|---|
| Baseline (within 2 weeks of initiation) | CBC, CMP (LFTs, lipase, amylase, alk phos, bilirubin), CRP |
| Week 4 | LFTs, lipase, amylase, bilirubin |
| Week 12 (if cycle extends) | LFTs, lipase, amylase, bilirubin, CRP |
| Prior to any chronic (>6 month) course | Colonoscopy |
The colonoscopy requirement is the one piece of monitoring most often skipped by gray-market users and the one with the most defensible mechanistic basis. The compound is pro-proliferative on intestinal epithelium — unresected adenomatous polyps are a hard stop, and personal history of GI malignancy is a hard contraindication. For short 4–8 week courses in users with no GI risk factors and no symptoms, the bloodwork-only cadence above is the community standard; for anything approaching chronic use, colonoscopy is not optional.
Stack Timing#
Teduglutide pairs cleanly with the rest of the gut-repair toolkit and does not require staggered timing:
- BPC-157 (250–500 mcg SC BID) — co-administered throughout the cycle; canonical pairing for mucosal and vascular repair
- KPV (250–500 mcg SC daily) — added for inflammatory-tone control in users with IBS or post-antibiotic dysbiosis
- L-glutamine (10–20 g/day oral) and butyrate — nutrient layer beneath the peptide signal
- GLP-1 agonists — generally run sequentially (teduglutide after GLP-1 discontinuation for villus restoration) rather than concurrently, unless the explicit goal is the combined GLP-1/GLP-2 anti-inflammatory effect
"GLP-2 analogs such as teduglutide have demonstrated the ability to preserve intestinal barrier integrity and reduce low-grade inflammation in preclinical studies." — Pálsson et al., Peptides (2024)
GH-axis peptides (tesamorelin, CJC/ipamorelin) amplify the IGF-1-mediated trophic effect and are run cautiously alongside teduglutide — the additive proliferative tone is the reason to be conservative with cycle length when stacking that direction.
Cycle Frequency#
Two to three short courses per year is the upper end of what most experienced users run. There is no documented benefit to continuous dosing outside the SBS indication, and the proliferative signaling argues against it. A reasonable cadence:
- 4–8 week course targeting a specific insult (heavy oral cycle, post-prep recovery, post-GLP-1)
- 3–6 month washout
- Repeat course if symptoms or absorption markers warrant it
PCT is not required. No hormonal recovery is needed. The cycle ends, the labs get checked, and the next course is scheduled when there's a reason to run one — not on autopilot.
Risks & mistakes
Common (most users)#
- Abdominal pain, bloating, and distension — the most frequently reported effects in the STEPS program, reflecting the intestinotrophic mechanism itself. Usually peaks in the first 2–4 weeks and attenuates as mucosal adaptation stabilizes. Splitting doses across rotating SC sites and avoiding aggressive caloric surplus during the initial weeks reduces intensity.
- Nausea — typically mild, often tied to the post-injection window. Administering in the evening with a small protein-containing meal blunts it for most subjects.
- Injection-site reactions — erythema, hematoma, transient nodules. Rotate between abdomen, thigh, and upper arm; use a fresh insulin pin per injection; allow the reconstituted solution to reach room temperature before SC dosing.
- Headache — usually transient in the first 1–2 weeks. Hydration and slight dose reduction resolve most cases.
- Peripheral edema / fluid retention — direct consequence of improved intestinal fluid absorption. Clinically meaningful in SBS subjects on parenteral support; for off-label users on sub-clinical doses, usually presents as mild ankle puffiness or scale weight bumping 1–2 lb in the first week. Reduce sodium intake and monitor.
- Upper respiratory symptoms — documented in trials but mechanism unclear; not typically dose-limiting.
Uncommon (dose-dependent or individual)#
- Elevated lipase and amylase — pancreatic enzyme bumps are well documented in the label. Check at baseline, 4 weeks, and 12 weeks. Persistent elevation >2× ULN warrants discontinuation regardless of symptoms.
- Elevated alkaline phosphatase and bilirubin — hepatobiliary signal driven by GLP-2R activity in the biliary tree. Monitored on the same schedule as lipase/amylase.
- Cholelithiasis / cholecystitis — gallbladder stasis can develop on longer courses. Right-upper-quadrant pain, fatty-food intolerance, or new reflux warrant ultrasound before continuing.
- Stomal or anastomotic narrowing — relevant for subjects with prior GI surgery. Mucosal hypertrophy at a pre-existing narrow segment can become symptomatic; new cramping, vomiting, or change in stool caliber means stop and image.
- Anti-teduglutide antibody formation — develops in a non-trivial minority on chronic dosing. Clinical impact appears limited but may explain attenuating response on long courses; a structured off-period is the practical answer.
- Fluid overload in subjects with compromised cardiac reserve — back off dose, restrict sodium, and reassess if dyspnea or rapid weight gain appears.
Rare but serious#
- Acute pancreatitis — severe persistent epigastric pain radiating to the back, with lipase elevation. Discontinue immediately and seek imaging.
- Mechanical bowel obstruction — vomiting, obstipation, escalating distension. The intestinotrophic mechanism makes this the signature serious event; subjects with prior bowel surgery carry the highest risk.
- Acceleration of pre-existing neoplasia — the mechanism that drives villus growth is bidirectional. Any new rectal bleeding, unintentional weight loss against a surplus, or change in bowel habit on chronic dosing demands colonoscopy without delay.
- Severe hypersensitivity — rare but reported. Angioedema or anaphylactoid reactions at injection sites are a stop signal.
Hard contraindications#
- Active or suspected GI malignancy — absolute. The compound is a mucosal mitogen; this line does not get crossed.
- Active non-GI malignancy, or any malignancy treated within the last 5 years — the proliferative signal is not organ-selective enough to justify the risk.
- Unresected colorectal polyps — a screening colonoscopy with polyp removal is required prior to initiation. This is the single most-skipped step in gray-market protocols and the most consequential one.
- Pregnancy and lactation — safety not established; do not use.
- Active pancreatitis or recent biliary disease — wait for resolution and normalized enzymes before any consideration of dosing.
- Known or suspected bowel obstruction — including symptomatic adhesive disease or untreated stomal stenosis.
- Severe, decompensated cardiac failure — improved fluid absorption is the wrong direction for this physiology.
Gender, fertility, and PCT considerations#
Teduglutide is non-hormonal. It does not bind androgen, estrogen, or progesterone receptors and has no documented effect on the HPG axis, LH, FSH, testosterone, estradiol, or SHBG. No PCT is required and no ancillary hormonal management is needed. The same per-kg dosing applies across the subject pool — dose is weight-scaled, not sex-scaled.
The compound should not be used during pregnancy or lactation; reproductive safety is not established and the mucosal-mitogen mechanism is the wrong pharmacology to be running through gestation. For users planning conception, there is no documented effect on semen parameters and no required washout — but a conservative approach is to complete any course and observe a 4-week off-period before conception attempts, simply because the chronic-exposure data outside SBS is thin.
The single monitoring point that matters more than all the others: colonoscopy before any course longer than ~6 months, and at 1 year on chronic use. The compound rewards informed users and punishes inattentive ones — not with acute toxicity, but with a slow proliferative signal that needs eyes on it.
FAQ — Teduglutide
Research & citations
5 studies cited on this page.
Conclusion
Teduglutide sits at the apex of gut-repair peptides — powerful, targeted, and reserved for protocols where true mucosal regeneration or barrier integrity is the goal rather than generic soft-tissue healing.
Key takeaways:
- Typical daily dose: 0.5–2.5 mg SC in common protocols; the clinical label is 0.05 mg/kg/day, but many community protocols use lower fixed dosing for cost and practicality
- Administration: once-daily subcutaneous injection, rotating sites (abdomen, thigh, upper arm); reconstitute with bacteriostatic water and store refrigerated
- Cycle duration: 4–12 weeks in gut-barrier repair or mucosal-regeneration stacks; not run continuously outside of clinical label scenarios
- Headline benefit: robust proliferation of enterocytes, increased villus height, improved nutrient absorption, and strong evidence for enhanced intestinal barrier function and reduced inflammation
- Most common stack: BPC-157 and KPV as synergists for gut healing; optional nutrient layer with glutamine or butyrate
- Monitoring: baseline and follow-up colonoscopy are mandatory for any long-term use due to the proliferative mechanism
For protocols demanding a true intestinotrophic effect, teduglutide delivers pharmacologically unique results, especially when stacked intelligently and cycled with respect for its power and risk profile.